Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New MET/MERTK/TRYO3/AXL inhibitors identified at Aucentra Therapeutics

Jan. 31, 2022

Betta Pharmaceuticals discovers CD73 inhibitors

Jan. 31, 2022

BridGene Biosciences divulges YAP1/TEAD interaction inhibitors

Jan. 28, 2022

Pfizer patents new JAK inhibitors

Jan. 28, 2022

Beta-elemene NO derivatives demonstrate potent antiglioma activity in vivo

Jan. 28, 2022

Sophoridine derivatives show improved potency against triple-negative breast cancer

Jan. 28, 2022

Loperamide shows antitumoral activity in TET2-mutated AML

Jan. 28, 2022

Somatic tissue engineering gives insights into ovarian cancer

Jan. 27, 2022

Synergistic antitumor activity of rencofilstat + anti-PD-1 in mice with fatty livers and HCC

Jan. 27, 2022

CGeneTech identifies new CDK inhibitors

Jan. 27, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...